Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA

Authors:

Top Cited Papers
Open Access
Abstract
No abstract available
Funding Information
  • Bristol-Myers Squibb Co

This publication has 35 references indexed in Scilit: